|
  
- 现金
- 1439 元
- 精华
- 0
- 帖子
- 1310
- 注册时间
- 2019-12-12
- 最后登录
- 2022-12-17
|
本帖最后由 tim889 于 2022-8-4 17:06 编辑
所谓的依据原文在这里：Simplifying Treatment Criteria in Chronic Hepatitis B: Reducing Barriers to Elimination （https://doi.org/10.1093/cid/ciac385）
这篇文章根本不是什么指南。事实上Hepatitis B Foundation是主要提供信息的非盈利组织，自己从不发布什么指南。Hep B foundation的主页上列举的都是EASL，AASLD和WHO的指南（https://www.hepb.org/treatment-a ... linical-guidelines/）。美国的医生主要参考的指南只有EASL和AASLD，偶尔会参考亚太的
这篇文章其实就是在吉利德赞助下 Rob Wong牵头和美国一家叫Quest Diagnostics做检测的公司和Hepatitis B Foundation的Robert G Gish合作研究了一下不同指南下符合治疗的人群的百分比，然后自己提出了四种简化标准，报告了一下每种标准下的符合治疗的人群的百分比是多少，仅此而已。就是数个数。文章的目的压根就不是说提出一个固定新标准。
自己看看这篇文章的作者都是收了谁的钱，我没有证据证明他们的目的，我不会胡说。但大家可以动脑子想想 写这文章的背后可能的目的是啥。
Notes
Financial support. This study was supported by Gilead Sciences (investigator-initiated research study grant).
Potential conflicts of interest. R. J. W. has received funding (to his insti- tution) from Gilead Sciences, and has served as a consultant and on the ad- visory board for Gilead Sciences. H. W. K., J. K. N., and H. K. are employees of and H. W. K. and H. K. own stock in Quest Diagnostics. R. G. G. reports grants received from Gilead Sciences; has served as an advisor or consultant to Abbott, AbbVie, Altimunne, Antios, Arrowhead, Dynavax, Eiger, Eisai, Enyo, Genentech, Genlantis, Gerson Lehrman Group, Gilead Sciences, Helios, HepaTX, HepQuant, Intercept, Janssen, Merck, Pfizer, Topography Health, Venatorx, Prodigy, Fibronostics, Fujifilm/Wako, Perspectum, Quest, and Sonic Incytes; has served on the data safety mon- itoring board for Altimmune, Arrowhead, CymaBay Therapeutics, and Durect; has served on the speaker’s bureau for AbbVie, BMS, Eisai, Genentech, Gilead Sciences, and Intercept; is a minor stock shareholder of RiboSciences and CoCrystal; and has received stock options from Eiger, Genlantis, HepQuant, and AngioCrine. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed. |
这也不是什么“美国传染病协会（IDSA）”发表的文章。IDSA 不制定HBV的治疗标准 。美国的标准是AASLD制定的。这是两个不同的组织。
至于“published on behalf of the Infectious Diseases Society of America.” 是指该杂志“Clinical Infectious Diseases”是Infectious Diseases Society of America.办的，由Oxford University Press代为编辑出版。并不是指这篇文章是Infectious Diseases Society of America发表的。 “Clinical Infectious Diseases” 的publisher就叫做“Oxford University Press on behalf of the Infectious Diseases Society of America”。该杂志的每一篇文章都有“Oxford University Press on behalf of the Infectious Diseases Society of America”的备注。负责该期刊的主编和editor们都是参加了Infectious Diseases Society of America的学者。由于这个journal不是open access的，那主要收入则从subscriber处来，所得收入则在Oxford University Press和Infectious Diseases Society of America之间分配。
写这么多其实是想告诉各位战友，微信的各种中文解读有些是不靠谱的，大概率大家没有阅读原文文献的能力，因此看了个微信标题就自以为懂了，这是很危险的。大家还是要找专业的医生，最好还是多问几个，因为有些医生都不明白文献在讲什么。而战友们只能找能把道理用浅显的语言跟病人说明白的医生。
最后，要谨防论坛里有些不学无术，还喜欢大言不惭，成天胡说八道的妄人。这些人不但自己看不懂原文，甚至连中文公众号也就读个标题。我还是先不点名了，有些人心里有数，好自为之吧。
|
|
发表于 2022-8-4 05:27
